
Jornal da USP: Anvisa (National Health Surveillance Agency) ratifies the safety of CAR-T therapy and authorizes the continuation of the clinical trial
After approval, the clinical trial will be able to recruit and treat patients with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin’s lymphoma at partner centers beginning in 2025.










